Biochemical Criteria for Metabolic Bone Disease
For routine diagnosis of metabolic bone disease, evaluation should be based on a combination of serum calcium, phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and 25-hydroxyvitamin D levels, measured serially rather than as single values. 1
Core Biochemical Panel
The essential biochemical markers include:
- Serum calcium (corrected total calcium)
- Serum phosphate
- Alkaline phosphatase (total or bone-specific)
- Parathyroid hormone (intact PTH)
- 25-hydroxyvitamin D
- 1,25-dihydroxyvitamin D (optional, particularly useful in certain contexts)
Serial measurements are critical because trends provide far more diagnostic value than isolated values, and therapeutic decisions should be based on patterns rather than single time points. 2, 3
Context-Specific Criteria
In Chronic Kidney Disease (CKD)
When GFR falls below 60 mL/min/1.73 m² (Stage 3 CKD), monitoring should begin with measurements of serum phosphorus, calcium, and PTH. 2
Key diagnostic thresholds in CKD:
- PTH <100 pg/mL (11.0 pmol/L): suggests adynamic bone disease
- PTH >500 pg/mL (55.0 pmol/L): suggests hyperparathyroidism
- PTH 100-500 pg/mL (11.0-55.0 pmol/L): insufficient sensitivity/specificity to distinguish bone disease types 2
Important caveat: Intact PTH assays overestimate biologically active PTH by detecting C-terminal fragments, which may have inhibitory activity. This limitation means PTH levels should be interpreted alongside other markers, particularly bone-specific alkaline phosphatase. 2
When PTH is in the indeterminate range (100-500 pg/mL) and the patient develops unexplained hypercalcemia, bone pain, or increased bone alkaline phosphatase, bone biopsy becomes useful for definitive diagnosis. 2
In Preterm Neonates
Metabolic bone disease of prematurity (MBDP) criteria:
- Serum phosphate <1.8 mmol/L (or <1.81 μmol/L) AND ALP >600 IU/L
- OR ALP >1000 IU/L alone 4
Early detection approach: ALP levels >500 IU/L at day of life 15 can serve as an early biomarker, allowing treatment initiation before radiological changes appear. 5
Peak PTH shows the best discrimination for radiographic osteopenia (optimal cut-off >28.7 pmol/L), outperforming ALP and phosphate in diagnostic accuracy. 6
In Chronic Intestinal Failure/Home Parenteral Nutrition
Biochemical assessment should include:
- Serum concentrations of calcium, magnesium, and phosphate
- 24-hour urinary excretion of these minerals (optional)
- Biochemical markers of bone turnover
- PTH levels
- 25-hydroxyvitamin D and possibly 1,25-dihydroxyvitamin D
- Serum aluminum concentrations in patients with low bone mineral density T-scores 1
Additional Markers and Urinary Assessments
Urinary measurements provide complementary information:
- Spot urine for calculation of tubular maximum reabsorption of phosphate per GFR (TmP/GFR)
- Urinary calcium:creatinine ratio
- 24-hour urinary calcium excretion 7
Bone turnover markers (serum or urinary) include osteocalcin, hydroxyproline, pyridinoline, and deoxypyridinoline, though their utility varies by specific metabolic bone disease. 8, 9
Critical Interpretation Principles
Biochemical markers alone cannot distinguish between osteomalacia and osteoporosis—bone densitometry (DXA) is required for this differentiation. For definitive histological diagnosis, bone biopsy remains the gold standard, though it is invasive and not routinely performed. 1
Context matters profoundly: The same biochemical value may have different implications depending on:
- The patient's kidney function (CKD affects interpretation of all markers)
- Concurrent medications (especially corticosteroids)
- Underlying disease processes
- Age and developmental stage
Avoid single-value decision-making: Treatment adjustments in CKD, for example, require monitoring calcium and phosphorus at least monthly for the first 3 months after therapy initiation, then every 3 months, with PTH measured every 3 months for 6 months, then every 3 months thereafter. 2
Common Pitfalls
- Over-reliance on PTH in CKD: PTH has insufficient sensitivity and specificity in the 100-500 pg/mL range to reliably predict bone disease type 2
- Ignoring vitamin D status: Both 25-hydroxyvitamin D deficiency and inappropriately normal 1,25-dihydroxyvitamin D levels (in the face of elevated PTH) contribute to metabolic bone disease 2
- Failing to exclude renal tubular disorders: Non-selective renal phosphate wasting suggests Fanconi syndrome rather than isolated metabolic bone disease—look for abnormal urinary losses of bicarbonate, amino acids, glucose, uric acid, and low molecular mass proteinuria 7
- Aluminum toxicity: Often overlooked but important, particularly in CKD patients with history of aluminum exposure; requires bone biopsy for definitive diagnosis before initiating deferoxamine therapy 2